Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  08:31 2022-12-05 pm EST
2086.50 JPY   -0.12%
12/02Syndax Pharmaceuticals Names Steve Sabus Chief Commercial Officer
MT
11/30Astellas Pharma Plans $360 Million Bond Sale
MT
11/18Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause

03/06/2022 | 06:39pm EST

TOKYO, March 7, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced topline results from the Phase 3 SKYLIGHT 4™ clinical trial investigating the long-term safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) which will support future regulatory filing submissions. VMS, characterized by hot flashes (also called hot flushes) and/or night sweats, are common symptoms of menopause.1,2

SKYLIGHT 4 is a randomized, placebo-controlled, double-blind Phase 3 clinical trial in over 1,800 women investigating the long-term (52-week) safety of fezolinetant in women seeking treatment for relief of VMS associated with menopause. The study's primary objectives were to evaluate the effect of fezolinetant on endometrial health and the long-term safety and tolerability of fezolinetant. The primary endpoint assessing endometrial health was achieved and the most common treatment emergent adverse events (TEAE) were headache and COVID-19, consistent with placebo. The topline data further characterize the long-term safety profile of fezolinetant and will inform future regulatory filings. Detailed results will be submitted for publication and for consideration at upcoming medical meetings.

"Based on our initial assessment, we are pleased with the outcome of the SKYLIGHT 4 study, which further characterizes the long-term safety of fezolinetant," said Nancy Martin, M.D., PharmD, Vice President, Global Medical Head, Medical Specialties, Astellas. "With these fezolinetant data, we are hopeful that we will have the opportunity to deliver a first-in-class, nonhormonal treatment option for moderate to severe VMS associated with menopause."

"Vasomotor symptoms are often reported as the most bothersome symptoms of menopause, yet there has been very little innovation in this therapeutic area," said Genevieve Neal-Perry, M.D., Ph.D., Chair, UNC School of Medicine Department of Obstetrics and Gynecology, "I am excited by the potential of a new nonhormonal treatment option for women experiencing moderate to severe VMS associated with menopause."

The SKYLIGHT 4 findings, along with the results from two pivotal Phase 3 clinical trials, SKYLIGHT 1™ and SKYLIGHT 2™, will provide the foundational data for regulatory submissions in the U.S. and Europe.

Fezolinetant is an investigational selective neurokinin-3 (NK3) receptor antagonist. The safety and efficacy of fezolinetant are under investigation and have not been established. If approved by regulatory authorities, fezolinetant would be a first-in-class, nonhormonal treatment option to reduce the frequency and severity of VMS associated with menopause.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 07 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 March 2022 23:38:08 UTC.


ę Publicnow 2022
All news about ASTELLAS PHARMA INC.
12/02Syndax Pharmaceuticals Names Steve Sabus Chief Commercial Officer
MT
11/30Astellas Pharma Plans $360 Million Bond Sale
MT
11/18Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome
MT
11/17Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as Fi..
AQ
11/16Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as Fi..
CI
11/08Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding..
CI
10/31Global markets live: IAG, Credit Suisse, Foxconn, General Motors, Bl..
MS
10/31Transcript : Astellas Pharma Inc., Q2 2023 Earnings Call, Oct 31, 2022
CI
10/31Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending ..
CI
10/26Actinium Pharmaceuticals' Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 ..
AQ
More news
Financials
Sales 2023 1 481 B 10 859 M 10 859 M
Net income 2023 207 B 1 519 M 1 519 M
Net cash 2023 414 B 3 036 M 3 036 M
P/E ratio 2023 18,3x
Yield 2023 2,87%
Capitalization 3 807 B 27 908 M 27 908 M
EV / Sales 2023 2,29x
EV / Sales 2024 2,12x
Nbr of Employees 14 522
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 2 089,00 JPY
Average target price 2 592,31 JPY
Spread / Average Target 24,1%
EPS Revisions
Managers and Directors
Kenji Yasukawa Chairman, President & Chief Executive Officer
Minoru Kikuoka Chief Financial Officer & Head-Finance
Yoshitsugu Shitaka Chief Scientific Officer & Head-Research
Katsuyoshi Sugita Head-Personnel & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.11.44%28 074
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.78%285 774